Citations Appearing in 2023

  1. Brunetti, L., Wang, L., Wassef, A., Gong, Y., Brinker, A., Buckley, B., Lipsky, P.E., Ondar, P., Poiani, G., Zhao, L. and Kong, A.N., 2023. Pharmacokinetics and Pharmacodynamics of Anthocyanins after Administration of Tart Cherry Juice to Individuals with Gout. Molecular Nutrition & Food Research, 67(9), p.2200550.
  2. Chung, E., 2023. Improving Precision of Vancomycin Dosing in Neonatal Sepsis based on Clinical Outcome Evaluation and Population Pharmacokinetics (Doctoral dissertation, University of Toronto (Canada)).
  3. Deshpande, D., Magombedze, G., Boorgula, G.D., Chapagain, M., Srivastava, S. and Gumbo, T., 2023. Ceftriaxone efficacy for Mycobacterium avium complex lung disease in the hollow fiber and translation to sustained sputum culture conversion in patients. The Journal of Infectious Diseases, p.jiad545.
  4. Drescher, S.K., Jiao, Y., Chen, M.J., Kurumaddali, A., Shao, J., Amini, E., Hochhaus, G. and Bulitta, J.B., 2023. Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics. Pharmaceutical research, 40(5), pp.1177-1191.
  5. Franco, E.J., Drusano, G.L., Hanrahan, K.C., Warfield, K.L. and Brown, A.N., 2023. Combination Therapy with UV-4B and Molnupiravir Enhances SARS-CoV-2 Suppression. Viruses, 15(5), p.1175.
  6. Giamberardino, C.D., Tenor, J.L., Toffaletti, D.L., Palmucci, J.R., Schell, W., Boua, J.V.K., Marius, C., Stott, K.E., Steele, S.L., Hope, W. and Cilla, D., 2023. Pharmacodynamics of ATI-2307 in a rabbit model of cryptococcal meningoencephalitis. Antimicrobial agents and chemotherapy, 67(10), pp.e00818-23.
  7. Gielecińska, A., Kciuk, M., Yahya, E.B., Ainane, T., Mujwar, S. and Kontek, R., 2023. Apoptosis, necroptosis, and pyroptosis as alternative cell death pathways induced by chemotherapeutic agents?. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, p.189024.
  8. Hanafin, P.O., Abdul Rahim, N., Sharma, R., Cess, C.G., Finley, S.D., Bergen, P.J., Velkov, T., Li, J. and Rao, G.G., 2023. Proof‐of‐concept for incorporating mechanistic insights from multi‐omics analyses of polymyxin B in combination with chloramphenicol against Klebsiella pneumoniae. CPT: Pharmacometrics & Systems Pharmacology, 12(3), pp.387-400.
  9. Huang, H.W., Wu, S., Chowdhury, E.A. and Shah, D.K., 2023. Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs. Journal of Pharmacokinetics and Pharmacodynamics, pp.1-18.
  10. Hudson, C.S., Smith, J.E., Eales, B.M., Nikolaou, M. and Tam, V.H., 2023. In vitro model to simulate multiple drugs with distinct elimination half-lives. International Journal of Antimicrobial Agents, 62(4), p.106924.
  11. Janzen, T., Tavola, F., Giussani, A., Cantone, M. and Uusijärvi, H., Compartmental model of [sup] 18 [/sup] F-choline. In Proc. of SPIE Vol (Vol. 7626, pp. 76261E-1).
  12. Jiao, Y., Yan, J., Vicchiarelli, M., Sutaria, D.S., Lu, P., Reyna, Z., Spellberg, B., Bonomo, R.A., Drusano, G.L., Louie, A. and Luna, B.M., 2023. Individual components of polymyxin B modeled via population pharmacokinetics to design humanized dosage regimens for a bloodstream and lung infection model in immune-competent mice. Antimicrobial Agents and Chemotherapy, 67(5), pp.e00197-23.
  13. Kim, J., Kim, T.H., Choi, J., Nam, K., Shin, B.S. and Shin, S., 2023. Novel modeling approach integrating population pharmacokinetics and interspecies scaling to predict human pharmacokinetics of the new anti-tuberculosis agent telacebec (Q203). Biomedicine & Pharmacotherapy, 167, p.115441.
  14. Li, X. and Jusko, W.J., 2023. Exploring the pharmacokinetic mysteries of the liver: application of series compartment models of hepatic elimination. Drug Metabolism and Disposition, 51(5), pp.618-628.
  15. Li, X. and Jusko, W.J., 2023. Utility of Minimal Physiologically Based Pharmacokinetic Models for Assessing Fractional Distribution, Oral Absorption, and Series-Compartment Models of Hepatic Clearance. Drug Metabolism and Disposition, 51(10), pp.1403-1418.
  16. Liu, Y., Moodley, M., Pasipanodya, J.G. and Gumbo, T., 2023. Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments. Antimicrobial Agents and Chemotherapy, 67(4), pp.e01401-22.
  17. Liu, Y., Moodley, M., Pasipanodya, J.G. and Gumbo, T., 2023. Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo Experiments. Antimicrobial Agents and Chemotherapy, 67(4), pp.e01401-22.
  18. Naware, S., Bussing, D. and Shah, D.K., 2023. Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies. Journal of Pharmacokinetics and Pharmacodynamics, pp.1-16.
  19. Nguyen, T.D., Bordeau, B.M. and Balthasar, J.P., 2023. Use of Payload Binding Selectivity Enhancers to Improve Therapeutic Index of Maytansinoid–Antibody–Drug Conjugates. Molecular Cancer Therapeutics, 22(11), pp.1332-1342.
  20. Nguyen, T.D., Smith, N.M., Attwood, K., Gundroo, A., Chang, S., Yonis, M., Murray, B. and Tornatore, K.M., 2023. Bayesian optimization of tacrolimus exposure in stable kidney transplant patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(10), pp.1032-1042.
  21. Rajadhyaksha, P.M., Shastri, D.H. and Shah, D.K., 2023. Pharmacokinetic Evaluation of Thermosensitive Sustained Release Formulations Developed for Subcutaneous Delivery of Protein Therapeutics. Journal of Pharmaceutical Sciences, 112(3), pp.868-876.
  22. Salehpour, N., Riley, L.D., Gonzales, M.J., Kobic, E. and Nix, D.E., 2023. Performance of Bayesian Area Under the Concentration-Time Curve-Based Pharmacokinetic Dosing Based on a One-Compartment Model and Trough-Only Monitoring for Vancomycin. Antimicrobial Agents and Chemotherapy, 67(6), pp.e00172-23.
  23. Sánchez-Herrero, S., Martínez, F.C., Serna, J., Cuquerella-Gilabert, M., Rueda-Ferreiro, A., Juan, A.A. and Calvet, L., 2023. Embedding R inside the PhysPK Bio-simulation software for pharmacokinetics population analysis. BIO Integration, 4(3), pp.97-113.
  24. Schmitt, A., Royer, B., Boidot, R., Berthier, J. and Ghiringhelli, F., 2023. Case report: 5-Fluorouracil treatment in patient with an important partial DPD deficiency. Frontiers in Oncology, 13, p.1187052.
  25. Sharma, A., Liu, X., Chandra, V., Rai, R., Benbrook, D.M. and Woo, S., 2023. Pharmacodynamics of Cyclin D1 Degradation in Ovarian Cancer Xenografts with Repeated Oral SHetA2 Dosing. The AAPS Journal, 26(1), p.5.
  26. Shin, E., Nantongo, M., Holland, S.M., Kreiswirth, B.N., Dousa, K.M. and bonomo, R.A., 2023, December. 2565. In vitro synergistic bacterial killing of imipenem and ceftaroline against Mycobacterium abscessus; a static concentration time-kill analysis. In Open Forum Infectious Diseases (Vol. 10, No. Supplement_2, pp. ofad500-2182). US: Oxford University Press.
  27. Shoji, K., Hikino, K., Saito, J., Matsui, T., Utano, T., Takebayashi, A., Tomizawa, D., Kato, M., Matsumoto, K., Ishikawa, T. and Kawai, T., 2023, December. 2566. Effect of CYP2C19 on Voriconazole Pharmacokinetics in Children with Malignancy or Inborn Errors in Immunity. In Open Forum Infectious Diseases (Vol. 10, No. Supplement_2, pp. ofad500-2183). US: Oxford University Press.
  28. Singh, S., Wang, J.Y., Heysell, S.K., McShane, P.J., Wadle, C., Shankar, P., Huang, H.L., Pasipanodya, J., Boorgula, G.D., Philley, J.V. and Gumbo, T., 2023. Omadacycline pharmacokinetics/pharmacodynamics in the hollow fiber model and clinical validation of efficacy to treat pulmonary Mycobacterium abscessus disease. International Journal of Antimicrobial Agents, 62(1), p.106847.
  29. Smith Nicholas, M. and Kathleen, T., Bayesian Optimization of Tacrolimus Exposure in Stable Kidney Transplant Patients.
  30. Stott, K.E., Ahmadu, A., Kajanga, C., Moyo, M., Gondwe, E., Chimang’anga, W., Chasweka, M., Unsworth, J., Jimenez-Valverde, A., Jagota, B. and Shah, R.V., 2023. Population pharmacokinetics and CSF penetration of flucytosine in adults with HIV-associated cryptococcal meningoencephalitis. Journal of Antimicrobial Chemotherapy, 78(4), pp.1015-1022.
  31. Świerczek, A. and Jusko, W.J., 2023. Pharmacokinetic/pharmacodynamic modeling of dexamethasone anti-inflammatory and immunomodulatory effects in LPS-challenged rats: a model for cytokine release syndrome. Journal of Pharmacology and Experimental Therapeutics, 384(3), pp.455-472.
  32. Tait, J.R., Harper, M., Cortés-Lara, S., Rogers, K.E., López-Causapé, C., Smallman, T.R., Lang, Y., Lee, W.L., Zhou, J., Bulitta, J.B. and Nation, R.L., 2023. Ceftolozane-tazobactam against Pseudomonas aeruginosa cystic fibrosis clinical isolates in the hollow-fiber infection model: challenges imposed by hypermutability and heteroresistance. Antimicrobial Agents and Chemotherapy, 67(8), pp.e00414-23.
  33. Viteri, A., Tucker, N., Flynn, R. and Foreman, J.K., 2023, December. 2567. Clinical Outcomes of Vancomycin Area-Under-the-Curve Monitoring: A Quasi-Experimental Study. In Open Forum Infectious Diseases (Vol. 10, No. Supplement_2, pp. ofad500-2184). US: Oxford University Press.
  34. Weiss, M. and Siegmund, W., 2023. Dependence of Bioavailability on Mean Absorption Time: What Does It Tell Us?. The AAPS Journal, 25(3), p.36.
  35. Weiss, M., 2023. Is the One-Compartment Model with First Order Absorption a Useful Approximation?. Pharmaceutical Research, 40(9), pp.2147-2153.
  36. Weiss, M., 2023. Relationship between dissolution rate in vitro and absorption rate in vivo of ketamine prolonged-release tablets. European Journal of Drug Metabolism and Pharmacokinetics, 48(2), pp.133-140.
  37. Xavier, R.M., Sharumathi, S.M., Parthasarathy, A.K., Mani, D. and Mohanasundaram, T., 2023. Limited sampling strategies for therapeutic drug monitoring of anti-tuberculosis medications: A systematic review of their feasibility and clinical utility. Tuberculosis, p.102367.